Pregnancy outcomes in dermatomyositis and polymyositis patients  by Missumi, Larissa Sayuri et al.
OP
p
L
J
a
b
a
A
R
A
A
K
D
I
O
P
P
h
2r e v b r a s r e u m a t o l . 2 0 1 5;5  5(2):95–102
www.reumato logia .com.br
REVISTA BRASILEIRA DE
REUMATOLOGIA
riginal article
regnancy  outcomes  in dermatomyositis  and
olymyositis patients
arissa Sayuri Missumia, Fernando Henrique Carlos de Souzaa,
oelma  Queiroz Andradea, Samuel Katsuyuki Shinjob,∗
Division of Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 17 May 2014
ccepted 6 October 2014
vailable online 6 January 2015
eywords:
ermatomyositis
nﬂammatory myopathies
bstetric intercurrences
olymyositis
regnancy
a  b  s  t  r  a  c  t
Background: Currently, there are few studies that describe pregnancy in dermatomyosi-
tis/polymyositis patients, and they are largely limited to case reports or studies with few
samples.
Objectives: Therefore, we describe the pregnancy in a large sample of patients with dermato-
myositis/polymyositis and to analyze the outcomes in those who became pregnant during
or  after disease onset.
Methods: The present single-center study analyzed 98 female patients with idiopathic
inﬂammatory myopathies (60 dermatomyositis and 38 polymyositis patients). They were
interviewed to obtain obstetric antecedent and demographic data from June 2011 to June
2012.
Results: Seventy-eight (79.6%) of the 98 patients had obstetric histories. Six polymyositis and
9  dermatomyositis patients became pregnant after disease onset. The pregnancy outcomes
in  these cases were good, except in the following cases: 1 disease reactivation, 1 intrauterine
growth retardation, 1 diabetes mellitus, 1 hypertension, 1 hypothyroidism, and 2 fetal losses
(same patient). Moreover, 2 patients developed dermatomyositis during pregnancy and 4 (2
polymyositis and 2 dermatomyositis) during the postpartum period with good control after
glucocorticoid and immunosuppressant therapy.
Conclusions: The adverse obstetric events were related to clinical intercurrences and the
pregnancy does not seem to carry a worse prognosis speciﬁcally in disease (for example:
disease relapsing). Moreover, dermatomyositis or polymyositis onset during pregnancy orthe  postpartum period had good outcome after drug therapy.
© 2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: samuel.shinjo@gmail.com (S.K. Shinjo).
ttp://dx.doi.org/10.1016/j.rbre.2014.11.001
255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Desfechos  da  gestac¸ão  em  pacientes  com  dermatomiosite  e  polimiosite
Palavras-chave:
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Miopatias inﬂamatórias
Intercorrências obstétricas
Polimiosite
Gestac¸ão
r  e  s  u  m  o
Introduc¸ão: Há poucos estudos que descrevem a gravidez em pacientes com der-
matomiosite/polimiosite. São, em grande parte, limitados a relatos de casos ou estudos
com amostras pequenas.
Objetivos: Analisar a gestac¸ão em uma grande amostra de pacientes com der-
matomiosite/polimiosite e os desfechos naquelas que engravidaram durante ou depois do
início da doenc¸a.
Métodos: Foram analisados 98 pacientes do sexo feminino com miopatias inﬂamatórias
idiopáticas (60 com dermatomiosite e 38 com polimiosite). Elas foram entrevistadas entre
junho de 2011 e junho de 2012 para coletar seus antecedentes obstétricos e dados demográ-
ﬁcos.
Resultados: Tinham antecedentes obstétricos 78 (79,6%) das 98 pacientes. Seis pacientes
com  polimiosite e nove com dermatomiosite engravidaram após o início da doenc¸a. O des-
fecho da gravidez nessas pacientes foi bom, exceto nos seguintes casos: um de reativac¸ão da
doenc¸a,  um de retardo do crescimento fetal, um de diabetes mellitus, um de hipertensão arte-
rial,  um de hipotireoidismo e dois de aborto (mesma paciente). Além disso, duas pacientes
desenvolveram dermatomiosite durante a gravidez e quatro (duas polimiosite e duas der-
matomiosite) durante o período pós-parto, com bom controle a seguir com glucocorticoides
e  terapia imunossupressora.
Conclusões: Os eventos obstétricos adversos estiveram relacionados com as intercorrências
clínicas e a gravidez não parece levar especiﬁcamente a um pior prognóstico na doenc¸a (por
exemplo: recidiva). Além disso, a dermatomiosite ou polimiosite de início durante a gestac¸ão
ou  no período pós-parto apresentou boa evoluc¸ão depois do tratamento farmacológico.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Dermatomyositis (DM) and polymyositis (PM) are systemic
inﬂammatory autoimmune myopathies characterized by the
subacute onset of symmetric weakness in the proximal mus-
culature. Furthermore, cutaneous manifestations, such as
heliotrope rash and Gottron’s papules, are present in DM.
Additionally, extra-muscular manifestations, such as articu-
lar, cardiorespiratory and gastrointestinal abnormalities may
be found in both diseases.1,2 The annual incidence of DM/PM
is 0.5–8.4 cases per million habitants, affecting twice as many
women as men, with no racial predilection. The DM affects
both children and adults, whereas PM is seem after the forth
decade of life and very rarely in childhood.3–5
Various studies conducted worldwide have assessed preg-
nancy in systemic rheumatic diseases. In systemic lupus
erythematosus, for example, the maternal mortality risk is 20
times higher than that of a healthy pregnant female. These
women also have a high risk of cesarean delivery, preterm
labor, preeclampsia, thromboembolic events, and infectious
and hematological complications.6 For rheumatoid arthritis,
various studies have shown improvement of symptoms during
pregnancy.7 However, especially in active rheumatoid arthri-
tis, there is a slight increase in the rate of children with
decreased birth weight and gestational age.8
Currently, there are few studies that describe pregnancy in
DM/PM patients, and they are largely limited to case reports or
studies with small samples.9–27 Thus, little is known about the
effects of pregnancy on DM/PM, whether these patients ﬁndit harder to conceive or if pregnancy outcomes are adversely
affected by myositis. Herein, we evaluate pregnancy in a large
sample of DM/PM patients and describe the outcomes in those
who became pregnant during or after disease onset.
Materials  and  methods
The present retrospective cohort study was performed at a sin-
gle center and included 98 consecutive DM/PM patients (≥18
years old) from June 2011 to June 2012. All patients met  at least
four of the ﬁve Bohan and Peter criteria items,28 and they were
regularly following at our myopathy unit of our tertiary care
center from 1993 to 2012. Patients with other associated sys-
temic autoimmune disease were not included in the present
study.
The study was approved by the local ethics committee, and
all of the study participants signed an informed consent form.
All of the participants underwent a standardized interview,
and their medical charts were extensively reviewed. The fol-
lowing data were collected: basic demographic data, age of
disease onset, treatment, number of pregnancies before and
after disease onset, activity of the disease during pregnancy
and pregnancy outcomes.
TherapyThe patients were initially treated with corticosteroids (oral
prednisone, 1 mg/kg/day), with later gradual dose reduc-
tion according to clinical and laboratory stability. When
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isease was severe (progression of dyspnea, dysphagia,
igniﬁcant loss of muscle strength), pulse therapy with
ethylprednisolone (1 g/day for three consecutive days) was
erformed. The following corticosteroid sparing agents were
sed as monotherapy or in combination: methotrexate
20–25 mg/week), azathioprine (2–3 mg/kg/day) or cyclosporine
2–4 mg/kg/day), chroloquine diphosphate (3–4 mg/kg/day),
nd cyclophosphamide (0.5–1.0 g/m2 of body surface). The
yclophosphamide was used in the presence of progressive
yspnea associated with pulmonary parenchymal change
onﬁrmed on computed tomography (“ground-glass” opacity
f honeycombing).
tatistical  analysis
he data are expressed as the mean and standard deviation
SD) for continuous variables or as frequencies and percent-
ges for categorical variables.
esults
bstetrical history was noted in 78 (79.6%) out of 98 women
ith DM/PM (Fig. 1). Of these, 57 women, who were not
escribed in this study, had a pregnancy before the onset of
M/PM.
Of the remaining patients, 15 became pregnant after
isease diagnosis; whereas 2 women developed the dis-
ase during pregnancy and 4 postpartum mothers developed
M/PM. In total, there were 50 pregnancies, and 10 women had
 history of miscarriage. Twelve patients had 2–7 pregnancies,
nd 1–4 pregnancies occurred before the DM/PM diagnosis.
The average age of pregnant women with established dis-
ase was 30.6 ± 3.7 years (range 22–37 years), with a mean
uration of disease of 13.4 ± 4.3 years. There were 9 cases of
M and 6 PM in a total of 21 pregnancies. Among the clinical
omplications, there were 2 fetal losses, 1 case of intrauter-
ne growth retardation, 1 case of decompensated gestational
iabetes mellitus, 1 case of systemic arterial hypertension, 1
ase of decompensated hypothyroidism and 1 case of venous
hrombophilia. Only 1 case had worsening disease status, for
• 57 women: had a pregnant before the onset of DM/PM 
• 15 women: had a pregnant after the onset of DM/PM
• 02 women: had  DM during pregnancy
• 04 women: had  DM/PM in postpartum period
98 women with DM/PM
Obstrical history?
Yes No
78 women (79.6%)  20 women (20.4%) 
Total of  50 pregnancies
12 women had 2-7 pregnancies
10 women had a history of miscarriage 
ig. 1 – Description of dermatomyositis and polymyositis
atients. 1 5;5  5(2):95–102 97
which corticosteroids were reintroduced, and good disease
control was achieved. Four patients received corticosteroids
throughout pregnancy with good clinical and laboratory dis-
ease control (Table 1).
In 2 cases, the disease (DM) developed during the preg-
nancy (Table 2). Particularly in the patient n◦ 16, the
corticosteroid was started two months later, since the cuta-
neous lesions were initially attributed to allergic reaction and
the progressive muscle weakness was not so clinically evident.
In four cases, DM/PM were diagnosed in the postpartum
period (Table 3).
Discussion
Herein, we assessed pregnancy in a large sample of DM/PM
patients and the outcomes in those who became pregnant
during or after disease onset.
There are various studies that analyze pregnancy in sys-
temic rheumatic diseases, but not in DM/PM. Hence, the
present study contributed to the few available studies in the
literature. Moreover, the advantage of this study was the anal-
ysis of obstetric antecedents in a large sample of DM/PM
patients.
There are two types of pregnancy-related myositis: one
presenting during pregnancy and the other, less common,
developing postpartum. In the present study, we  did not con-
sider the outcomes of pregnancies that occurred prior to the
diagnosis of DM/PM.
The evolution and behavior of pregnancy in inﬂammatory
myopathies that are either active or in remission is still con-
troversial in the literature. There is, for example, a description
of pregnancy in patients with frank DM/PM activity. However,
with the introduction of drug therapy, the disease is controlled
without complications after delivery.9–13 England et al.16
reported a case without neonatal complications but result-
ing in maternal death due to acute exacerbation of diabetes.
Silva et al.29 reported eight cases of disease development
postpartum. Gutierrez et al.30 observed three patients with
previously inactive disease that had an exacerbation during
pregnancy. Other studies have reported illness after childbirth
or abortion, suggesting that the fetus acts as a foreign body,
perpetuating disease activity only during pregnancy.18–21 In
this study, all patients had stable disease, and 4 patients used
corticosteroids to control the myopathy during pregnancy. In
contrast, only 1 case demonstrated clinical and laboratory
reactivation of the disease requiring corticosteroids, but with
good control of disease activity. From the obstetric standpoint,
with the exception of 6 cases, successful pregnancies without
feto-maternal complications were the rule in the peripartum
period.
There are few studies involving a large enough sam-
ple to allow generalizations about pregnancy in DM/PM
patients.9,29–32 Based on these studies, the main obstetric
complications described are intrauterine growth retardation,
prematurity and fetal death.In the present study, 2 women had three pregnancies after
disease onset. In 1 PM patient, gestational diabetes developed
in the third pregnancy. However, there was no reactivation of
disease in the peripartum or postpartum period. In the second
98
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Table 1 – General characteristics of pregnancy outcomes in dermatomyositis and polymyositis patients.
ID Mother’s
age
(years)
G/P/A Maternal
adverse event
Disease Disease
duration prior
to pregnancy
(years)
Disease
status at
pregnancy
Previous
therapy
Current
therapy (at
pregnancy)
Gestational
age (week)
Fetus weight
(g)
Fetal
adverse
event
1 33 6/0/5 Venous
throm-
bophilia
DM  12 Stable MTX 25 mg/week,
AZA 3 mg/kg/day, CD
4 mg/kg/day
CD
4  mg/kg/day
32w2d 2090 Healthy
1 35 7/1/5 Hypothyroidism DM 14 Stable MTX 25 mg/week,
AZA 3 mg/kg/day, CD
4 mg/kg/day
CD
4  mg/kg/day
Pred
10  mg/day
37w3d 2410 Healthy
2 30 2/1/0 Healthy DM 6 Stable AZA 3 mg/kg/day, CD
4 mg/kg/day
–  Healthy
2 35 3/2/0 Healthy DM 11 Stable AZA 3 mg/kg/day, CD
4 mg/kg/day
–  Healthy
3 28 1/0/0 Healthy DM 9 Stable MTX 25 mg/week,
AZA 3 mg/kg/day, CD
4 mg/kg/day
CD
4  mg/kg/day
Healthy
4 24 3/2/0 Healthy DM 6 Stable AZA 3 mg/kg/day – Healthy
5 22 1/0/0 Healthy DM 18 Stable AZA 3 mg/kg/day, CD
4 mg/kg/day
CD
4  mg/kg/day
3410  Healthy
6 33 1/0/0 Healthy PM 12 Stable AZA 3 mg/kg/day Pred
20 mg/day
3180  Healthy
7 29 1/0/0 Healthy DM 5 Stable CYC 0.5–1.0 g/bs2 – 3420 Healthy
8 34 4/1/2 Healthy PM 17 Stable AZA 3 mg/kg/day Pred
30 mg/day
39w1d 3090 Healthy
9 28 2/1/0 Healthy PM 13 Stable MTX 25 mg/week,
CD 4 mg/kg/day
–  Healthy
9 30 3/2/0 Healthy PM 15 Stable MTX 25 mg/week,
CD 4 mg/kg/day
–  Healthy
9 37 4/3/0 Diabetes
mellitus
PM  17 Stable MTX 25 mg/week,
CD 4 mg/kg/day
–  3390 Healthy
10 31 1/0/0 Healthy DM 13 Stable MTX 25 mg/week – Fetal loss
10 32 2/0/1 Healthy DM 14 Worse MTX 25 mg/week Pred
1 mg/kg/day
Fetal  loss
10 34 3/0/2 Healthy DM 16 Stable MTX 25 mg/week – 40w  IUGR
11 33 2/1/0 Healthy PM 21 Stable MTX 25 mg/week – 3600 Healthy
12 30 1/0/0 Healthy PM 19 Stable MTX 25 mg/week,
AZA 3 mg/kg/day
Pred
20 mg/day
Healthy
13 29 3/2/0 Healthy PM 13 Stable MTX 20 mg/week – 3200 Healthy
14 30 3/2/0 Healthy DM 17 Stable AZA 3 mg/kg/day – Healthy
15 26 2/1/0 Hypertension,
healthy
DM  14 Stable AZA 3 mg/kg/day – Healthy
BS, body surface; ID, identiﬁcation; G, gravida (pregnancies); P, parity (births); A, spontaneous abortion; IUGR, intrauterine growth retardation.
Drugs: AZA, azathioprine; CD, chroloquine diphosphate; CYC, cyclophosphamide; MTX, methotrexate; Pred, prednisolone.
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Table 2 – Two dermatomyositis onset at the pregnancy.
ID Mother’s
age (years)
G/P/A Maternal
adverse event
Disease Clinical and
laboratory
features
Therapy Gestational
age  (week)
Cesarean
delivery (w)
Apgar
score
Fetus
weight (g)
Fetal
adverse
event
16 29 1/0/0 Diabetes
Hypertension
DM Progressive symmetrical
weakness muscle,
heliotrope rash, Gottron’s
papules, creatine kinase
494 IU/L, aldolase 173 IU/L,
electromyography
(proximal limb myopathy)
After  two months, Pred
1 mg/kg/day were started
with good results. After
parturition, AZA and
subsequently, MTX and CP
were associated with good
disease control
24  37 8/9/9 3210 Healthy
17 26 1/0/0 Hypothyroidism DM Dysphagia, progressive
symmetrical weakness
muscle, heliotrope rash,
Gottron’s papules, creatine
kinase 22858 IU/L, aldolase
159 IU/L, electromyography
(proximal limb myopathy)
Pred  1 mg/kg/day. After
parturition, MTX was
associated with good
disease control
25  38 9/10/10 3000 Healthy
ID, identiﬁcation; G, gravida (pregnancies); P, parity (births); A, spontaneous abortion.
Drugs: AZA, azathioprine; CP, cyclosporine; MTX, methotrexate; Pred, prednisolone.
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Table 3 – Four dermatomyositis/polymyositis that were  diagnosed in the postpartum period.
ID Mother’s
age
(years)
G/P/A Maternal
adverse event
Disease Clinical and
laboratory features
after parturition
Therapy  Cesarean
delivery
(week)
Apgar
score
Fetus
weight (g)
Fetal
adverse
event
18 35 3/0/0 – PM Two months after parturition:
progressive symmetrical weakness
muscle, creatine kinase 2300 IU/L,
aldolase 29 IU/L, electromyography
(proximal limb myopathy), muscle
biopsy consistent with an
inﬂammatory myopathy
Five months after symptom
onset, pred 1 mg/kg/day,
AZA and MTX were
initiated
40  9/10/10 3500 Healthy
19 32 3/0/2 Hypothyroidism PM Three months after parturition,
progressive symmetrical weakness
muscle, creatine kinase 12426 IU/L,
aldolase 175 IU/L,
electromyography (proximal limb
myopathy)
Started immediately, pred
1 mg/kg/day, MTX, AZA.
Symptoms improved after 8
months of clinical drug
therapy
36  – – Fetal death
(intrauterine
fetal
maceration
and hypoxia)
20 24 1/0/0 DM Two months after parturition,
progressive symmetrical weakness
muscle, creatine kinase 4100 IU/L,
aldolase 45 IU/L, electromyography
(proximal limb myopathy),
heliotrope rash, Gottron’s papules
Started immediately, pulse
therapy with
methylprednisolone
(1 g/day for three
consecutive days), followed
by pred 1 mg/kg/day plus
cyclophosphamide.
Subsequently, initiated AZA
and MTX with good disease
control.
39 9/10/10 3200 –
21 25 2/0/0 DM One month after parturition,
progressive symmetrical weakness
muscle, creatine kinase
22,000 IU/L, aldolase 45 IU/L,
electromyography (proximal limb
myopathy), heliotrope rash,
Gottron’s papules
Started immediately pred
1 mg/kg/day plus AZA, CP
and MTX with good disease
control
39 9/10/10 3300 –
ID, identiﬁcation; G, gravida (pregnancies); P, parity (births); A, spontaneous abortion.
Drugs: AZA, azathioprine; CP, cyclosporine; CYC, cyclophosphamide; MTX, methotrexate; Pred, prednisolone.
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ase, a patient with DM,  there were 2 fetal losses; during
er second pregnancy, she experienced disease reactivation
s previously mentioned. In the third pregnancy, she had
ntrauterine growth retardation, but with stable disease. In
eneral, there were no signiﬁcant pregnancy complications
n our sample, probably because the majority of patients had
table disease.
Concerning fertility, it has been suggested that the rates are
igniﬁcantly different before and after the onset of DM/PM.9
owever, the late age of onset and the use of contraceptives
reclude an accurate evaluation of the inﬂuence of the disease
n fertility. Different follow-up periods, lack of information
n the use of contraception and a scarcity of cases also make
his analysis difﬁcult. In the present study, 6 patients had new
regnancy after the onset of DM/PM. Moreover, one of them
ad two pregnancies after disease onset.
In the present study, in four cases, DM/PM onset occurred
uring the postpartum period. In all of these cases, there was
ood control of the disease after the introduction of corti-
osteroids and immunosuppressive drugs. Kofteridis et al.14
escribed an acute onset of diabetes in pregnancy that lead to
habdomyolysis and fetal loss. Autoimmune disease may be
nduced as a result of maternal hormonal changes, alteration
f immune function during pregnancy or as a consequence of
aternal exposure to fetal antigens,33 which may explain the
nset of DM/PM in the postpartum period.
There are some limitations to the present study. Our study
s limited by its retrospective cohort study design. Further-
ore, this work includes the characteristics of the study
opulation, which were from a tertiary care center and most
ikely represent a more  severe disease spectrum; therefore, the
requency of pregnancy and its repercussions in DM/PM might
ot have been well-estimated.
onclusions
he adverse obstetric events were related to clinical intercur-
ences and the pregnancy does not seem to carry a worse
rognosis speciﬁcally in disease (for example: disease relaps-
ng). Moreover, dermatomyositis or polymyositis onset during
regnancy or the postpartum period had good outcome after
rug therapy.
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